Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckRad-CD8
2017-003226-33Phase 2Completed
- Sponsor
- Friedrich-Alexander University Erlangen-Nuremberg
- Start
- Mar 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in head and neck squamous cell carcinoma (HNSCC) and Squamous cell carcinoma of the supraglottic larynx (SCCSL), sponsored by Friedrich-Alexander University Erlangen-Nuremberg. Primary endpoint: Protocol treatment feasibility through cycle 6. Started Mar 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Squamous cell carcinoma of the supraglottic larynx (SCCSL)
Beyond the preview
Go deeper on 2017-003226-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003226-33.